At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

This report has data at SICBL, ICB and Commissioning Region level and focuses on the cardiovascular MO opportunities:

  • Identifying patients with atrial fibrillation and using best value direct-acting oral anticoagulants
  • Identifying patients with hypertension and starting antihypertensives where appropriate
  • Optimising lipid management for cardiovascular disease prevention

NHS England Aims:

  • To increase the diagnosis of AF and anti-coagulate with the best value DOAC where clinically appropriate.
  • Identify patients with hypertension and start antihypertensives when appropriate.
  • Increase the proportion of patients with CVD prescribed a statin and 2nd line therapies where required, to optimise lipid management. Reduction in CVD deaths, and hospital admissions for MI and stroke.

The report is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at

This publication is part of our Strategic Support and Planning contract. To gain access please email us at   



Data period

January 2021 to December 2023